Business Context and Reporting Period
This Form 8-K reports on the Annual Meeting of Stockholders held by Context Therapeutics Inc. on June 13, 2024. The company is an emerging growth company incorporated in Delaware, with its common stock (Symbol: CNTX) trading on The Nasdaq Stock Market.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
As of the record date (April 15, 2024), there were 15,966,053 shares outstanding. A quorum was established with 8,486,458 shares (53.15%) present. The following proposals were approved:
- Proposal 1: Ratification of Auditor Stockholders ratified the appointment of CohnReznick LLP for the fiscal year ending December 31, 2024.
- For: 8,364,879
- Against: 117,835
- Abstentions: 3,744
- Proposal 2: Election of Directors Five nominees were elected to serve until the 2027 Annual Meeting.
- Richard Berman: 4,774,152 For; 1,873,694 Withheld
- Dr. Philip Kantoff: 6,047,097 For; 600,749 Withheld
- Martin Lehr: 6,637,406 For; 10,440 Withheld
- Jennifer Evans Stacey: 5,028,962 For; 1,618,884 Withheld
- Linda West: 6,063,962 For; 583,884 Withheld
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, management commentary on future outlook, specific risks, contingencies, or unusual items. The document is limited to the disclosure of voting outcomes.
Investor Verification Checklist
- Verify the tenure of the newly elected directors, specifically noting their terms extend to the 2027 Annual Meeting.
- Confirm the appointment of CohnReznick LLP as the independent auditor for the 2024 fiscal year.
- Review the significant number of broker non-votes (1,838,612) recorded for the director elections to understand potential proxy voting dynamics.
- Check subsequent filings for the company's financial performance, as this 8-K contains no financial data.